MiR‐766‐3p Inhibits Pancreatic Cancer Cell Growth
Author Information
Author(s): Zhipeng Quan, Ziwei Yin, Yuelin Huang, Xuemei Huang, Hao Huang, Qingrong Mo, Jianhua Gong, Lingyun Liu, Yi Zhou, Yaqun Yu
Primary Institution: Affiliated Hospital of Guilin Medical University
Hypothesis
MIR‐766‐3P expression is associated with pancreatic cancer development and progression.
Conclusion
MIR‐766‐3P inhibits pancreatic cancer cell proliferation and stemness by targeting MAPK1 and regulating the MAPK/ERK pathway.
Supporting Evidence
- MIR‐766‐3P expression was significantly lower in pancreatic cancer tissues compared to normal tissues.
- High levels of MIR‐766‐3P were associated with better prognostic outcomes in pancreatic cancer patients.
- MIR‐766‐3P overexpression inhibited pancreatic cancer cell growth and stemness.
- MIR‐766‐3P directly targets MAPK1, affecting the MAPK/ERK signaling pathway.
- MAPK1 expression was found to be negatively correlated with MIR‐766‐3P levels in pancreatic cancer tissues.
- Animal studies showed that MIR‐766‐3P mimics reduced tumor growth in vivo.
Takeaway
MIR‐766‐3P is like a superhero for pancreatic cancer cells, helping to stop them from growing and spreading.
Methodology
The study used miRNA RT‐PCR, western blot, qRT‐PCR, gain/loss-of-function assays, RNA sequencing, and luciferase reporter assays.
Participant Demographics
50 pancreatic cancer patients and 50 matched adjacent tissue samples.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website